巴西批准世界首款单剂登革热疫苗

Core Insights - The Butantan Institute in Brazil has developed the world's first single-dose dengue vaccine, which has been approved by the Brazilian Health Regulatory Agency for use in individuals aged 12 to 59 years [1] - The vaccine demonstrates a total efficacy of nearly 75% and over 90% efficacy in preventing severe cases, comparable to the currently used two-dose imported vaccines but with the advantage of requiring only one dose [1] - To expand production capacity, the Butantan Institute has partnered with a Chinese company, aiming to supply approximately 30 million doses by the second half of 2026 [1] - The vaccine is expected to be included in Brazil's national immunization program, although the specific timing and age groups for vaccination are yet to be determined by the government [1] - The Brazilian Ministry of Health reported over 6.5 million suspected dengue cases and more than 6,300 deaths in 2024, with over 1.63 million suspected cases still reported as of November 22, 2025 [1] Company and Industry Summary - The Butantan Institute's vaccine represents a significant breakthrough in Brazil's scientific and health sectors, addressing a long-standing public health issue with an effective single-dose solution [1] - The collaboration with a Chinese company for vaccine production indicates a strategic move to enhance manufacturing capabilities and meet the anticipated demand for dengue vaccination in Brazil [1] - The ongoing dengue outbreak in Brazil highlights the urgent need for effective vaccination solutions, as evidenced by the high number of suspected cases and fatalities reported in recent years [1]